Has Alpelisib been successfully included in the medical insurance directory in 2025?

Alpelisib (Alpelisib) is a targeted drug used to treat PIK3CA mutation-positive breast cancer. In recent years, it has gained great attention in the field of international cancer treatment. However, as of 2025, Apelvis has not yet been officially launched in China, and therefore has not been included in the national medical insurance directory. This means that domestic patients are temporarily unable to purchase and use the drug through formal medical channels.

Since Apelvis has not yet entered the domestic market, patients can only seek drug sources through overseas channels. It is understood that the price of the original Apelis drug produced in India is about more than 3,000 yuan, which is more affordable than expected domestic prices. As an important producer of generic drugs in the world, India's original research and generic drugs are widely recognized in terms of quality and efficacy, making them the choice of some patients.

In addition, Apelisi also has imitation versions produced in countries such as Laos in overseas markets, and the price is even lower, about more than 1,000 yuan. This generic drug is basically the same as the original drug in terms of drug ingredients and therapeutic effects, which greatly reduces the financial burden on patients and is especially suitable for patients who cannot afford the high price of the original drug.

Generally speaking, Apelvis2025 has not yet been included in the domestic medical insurance system, and patients have limited access to the drug and there are certain difficulties. In the future, with the progress of approval and adjustments to medical insurance policies, Apelvis is expected to officially enter the domestic market and medical insurance catalog, improving its accessibility and providing effective treatment options for more qualified patients.

Reference materials:https://www.drugs.com/